How about the various assays that test for changes of the individual drug resistance systems mentioned above? Although the discussion of technical aspects would go too far, we have to be aware of the fact that a multitude of pathophysiological aspects can be measured, starting from alterations of gene regulation, the gene itself, its message, protein expression, phos-phorylation and, finally, the function and activity of a certain protein. So the measurement of, for example, the amount of protein present may just tell a part of the whole story. If these parameters are found in a tumor not having been exposed to cytostatic drugs then it may just be a hypothesis that proteins like the MDR1 product p-glycoprotein (p-gp) have anything to do with intrinsic drug resistance. This hypothesis has beautifully been tested in leukemias, lymphomas and multiple myelomas where clinical trials with MDR-modifying agents have demonstrated that drug resistance was correlated with the emergence of p-gp in tumor cells and that tumors which have become resistant to chemotherapy again became sensitive if the same chemotherapy was given with the addition of MDR modifiers [8] [9] [10] . So this would confirm that the emergence of p-gp during chemotherapy is not just a new risk factor but is clinically relevant and even 'treatable'. But still the data are too controversial to already advise colleagues to determine these parameters on a routine basis. The determination of p-gp is probably close to routine use in leukemias and myelomas, but measurements © 1993 S. Karger GmbH, Freiburg such as topoisomerase II, thymidilate synthase or metallothio-nein levels need to be evaluated further before they can be introduced into the clinic. What about the impact of such resistance parameters at initial diagnosis of a tumor, at a time when no chemotherapy has been given which could have selected for clones expressing, for example, p-gp or an elevated GST pi? Again, from Volm and Mattern's work we could conclude that the measurement of these parameters may be clinically relevant. However, the basic problem remains in the case of NSCLC that we do not have substances that are potent enough to treat lung cancer. Cytostatic treatment so far has had little impact on the outcome of NSCLC because the currently available drugs are unable to satisfactorily eradicate the tumor cells. Still it seems that drug sensitivity in NSCLC may be related to p-gp and other resistance parameters. Therefore the question comes up whether MDR modifiers given together with initial chemotherapy may render these tumors more drug-sensitive. Unfortunately, until now there are no data showing that an intrinsically resistant tumor which, for example, is p-gp-positive responds to chemotherapy if it is given together with an MDR modifier. Why is that so? There is probably a multitude of other resistance-related systems whose function we currently do not know. A system such as MDRl/p-gp may have a significant impact on one tumor type whereas it may just be an epiphenomenon in another one. Many resistance systems probably act together and, therefore, their impact can only be quantified if they are individually measured and put in relation to each other. We still seem to be at the beginning of understanding drug resistance. We have discovered some pieces of the puzzle that may be clinically relevant in a fraction of the tumors we know. It is our opinion that at this time it is too early to use any of these global tests or determinations of individual MDR mechanisms as a routine analysis. The evaluation of such factors should be implemented into clinical trials so that we can learn more about the basic pathophysiology of the resistance phenomenon. This task can only be accomplished if clinicians, patho-logists and molecular biologists further intensify their close collaboration.
